Novartis takes fight to Pfizer's Ibrance with new Kisqali data

ZURICH (Reuters) - New data from Novartis's breast cancer drug Kisqali underscored its effectiveness in pre-menopausal women, the Swiss drugmaker said, amid efforts to muscle in on turf dominated by rival Pfizer's Ibrance.